# Burning Mouth Syndrome as a Central Pain Disorder: A Case Study Demonstrating Response to Occipital Nerve Block Treatment

**Authors:** Shachar Zion Shemesh, Paz Kelmer, Lior Ungar

PMC · DOI: 10.3390/dj14020081 · 2026-02-02

## TL;DR

A man with chronic mouth burning pain found full relief through nerve blocks targeting central pain pathways, suggesting a new treatment approach.

## Contribution

Demonstrates that occipital nerve blocks can effectively treat Burning Mouth Syndrome by modulating central pain circuits.

## Key findings

- Occipital nerve blocks led to complete remission of Burning Mouth Syndrome in a male patient.
- Pain reduction increased with successive nerve blocks, reaching 100% relief after the third block.
- A mild recurrence responded fully to a fourth block, maintaining pain-free status for a year.

## Abstract

Background: Burning Mouth Syndrome (BMS) is a chronic orofacial pain condition characterized by a burning sensation in the oral cavity without identifiable lesions. It predominantly affects women (especially postmenopausal) but can occur in men. BMS is considered a multifactorial neuropathic pain disorder involving both peripheral small-fiber neuropathy and central dysregulation, often accompanied by taste alterations (dysgusia) and xerostomia despite normal oral exams. Treatment is challenging, with modest responses to agents like clonazepam, tricyclic antidepressants, or gabapentinoids. Observations: We present a 67-year-old male with recalcitrant primary BMS who showed complete remission temporally associated with occipital nerve blockade, likely affecting central trigeminocervical pathways. Initial therapy with amitriptyline (25 mg) and gabapentin (900 mg/day) yielded ~30% pain relief. Given suspected central sensitization, greater and lesser occipital nerve (GON) blocks were administered in series. After the first, second, and third ON blocks, pain was reduced by ~50%, 80%, and 100%, respectively. Remission persisted at one-year follow-up under continued medications. A mild recurrence (~20% of baseline pain) responded fully to a fourth GON block, maintaining another year of pain-free status. Lessons: This case underscores the complex central mechanisms in BMS and illustrates that modulating central pain circuits via occipital nerve blockade, through trigeminocervical convergence mechanisms, without direct trigeminal intervention. We discuss the diagnostic challenges of BMS, the rationale of occipital neuromodulation, and how this novel therapeutic strategy compares with current literature, supporting the hypothesis of central sensitization in BMS.

## Linked entities

- **Chemicals:** amitriptyline (PubChem CID 2160), gabapentin (PubChem CID 3446)
- **Diseases:** Burning Mouth Syndrome (MONDO:0006687)

## Full-text entities

- **Genes:** TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}
- **Diseases:** nociceptive (MESH:D059226), cluster headache (MESH:D003027), benign prostatic hypertrophy (MESH:D011470), ischemic heart disease (MESH:D017202), infection (MESH:D007239), nutritional deficiencies (MESH:D044342), hypertension (MESH:D006973), craniocervical pain syndromes (MESH:D020196), Symptom (MESH:D012816), stellate ganglion (MESH:D045888), neuropathies (MESH:D009422), migraine (MESH:D008881), cervicogenic headache (MESH:D051298), clinical (MESH:D000075902), neurogenic inflammation (MESH:D020078), soreness (MESH:D063806), candidiasis (MESH:D002177), pain syndromes (MESH:C538101), chronic pain (MESH:D059350), depression (MESH:D003866), craniofacial neuralgias (MESH:D009437), trigeminal neuralgia (MESH:D014277), dry mouth (MESH:D014987), type 2 diabetes mellitus (MESH:D003924), intracranial lesions (MESH:D020765), anxiety (MESH:D001007), headache disorders (MESH:D020773), diabetes (MESH:D003920), vascular disease (MESH:D014652), craniofacial pain syndromes (MESH:D005156), glossitis (MESH:D005928), dyslipidemia (MESH:D050171), occipital (MESH:D006259), sleep disturbances (MESH:D012893), Pain (MESH:D010146), dysgeusia (MESH:D004408), peripheral small-fiber neuropathy (MESH:D000071075), hematoma (MESH:D006406), Pain Disorder (MESH:D013001), cranial nerve tumor (MESH:D003390), taste disturbance (MESH:D013651), headache (MESH:D006261), inflammation (MESH:D007249), injury to (MESH:D014947), neuropathic disease (MESH:D004194), gastroesophageal reflux disease (MESH:D005764), neck pain (MESH:D019547), analgesia (MESH:D000699), abnormalities of the tongue, mucosa, or (MESH:D014060), hyperactivity (MESH:D006948), nerve (MESH:C537568), arrhythmic (OMIM:212500), BMS (MESH:D002054), facial pain (MESH:D005157), Psychological distress (MESH:D012128), GON (MESH:D012784), lingual nerve block (MESH:D061222), GON block (MESH:D006327), autoimmune (MESH:D001327), affective disorders (MESH:D019964)
- **Chemicals:** lidocaine (MESH:D008012), Greater (-), folate (MESH:D005492), glucose (MESH:D005947), gabapentin (MESH:D000077206), vitamin B12 (MESH:D014805), amitriptyline (MESH:D000639), steroid (MESH:D013256), capsaicin (MESH:D002211), gadolinium (MESH:D005682), Celestone (MESH:D001623), alpha-lipoic acid (MESH:D008063), clonazepam (MESH:D002998), benzocaine (MESH:D001566), iron (MESH:D007501)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12939458